Trial Profile

A pivotal clinical trial assessing BOS-580

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 30 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efimosfermin alfa (Primary)
Indications Non-alcoholic steatohepatitis
Focus Registrational; Therapeutic Use
Sponsors Boston Pharmaceuticals

Most Recent Events

23 Apr 2025 According to Boston Pharmaceuticals media release, Efimosfermin clinical program to advance to Phase 3 pivotal study in fourth quarter of 2025
15 Nov 2024 According to Boston Pharmaceuticals media release, company will have future discussions with regulatory authorities and anticipates advancing the clinical program to late-stage development in 2025.
21 Dec 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com